GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » FFO

Hua Medicine (HKSE:02552) FFO


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine FFO?

FFO (Funds from operations) only applies to REITs.


Hua Medicine Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Chen Li 2101 Beneficial owner
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Hong Jane Xingfang 2202 Interest of your spouse
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner